Cleveland BioLabs Phase II Hormone-Refractory Prostate Cancer Trial Advances to Next Phase

Cleveland BioLabs Phase II Hormone-Refractory Prostate Cancer Trial Advances to Next Phase: "CLEVELAND, April 5 /PRNewswire-FirstCall/ -- Cleveland BioLabs, Inc. (Nasdaq: CBLI; BSE: CFB), announced today that its Phase II efficacy study for Curaxin CBLC102 in advanced, hormone-refractory (androgen independent) prostate cancer has progressed to the next phase."